Cellular Cancer Immunotherapy in the Liver Transplant Population for HCC: An Attractive Therapeutic Option for the Next Decade

IF 1.9 4区医学 Q2 SURGERY

Clinical Transplantation Pub Date : 2025-09-13 DOI:10.1111/ctr.70313

Dongdong Yu, Shuchan Li, Hao Chen, Lidong Wang

{"title":"Cellular Cancer Immunotherapy in the Liver Transplant Population for HCC: An Attractive Therapeutic Option for the Next Decade","authors":"Dongdong Yu, Shuchan Li, Hao Chen, Lidong Wang","doi":"10.1111/ctr.70313","DOIUrl":null,"url":null,"abstract":"<div>\n \n <p>Immunocytotherapy has emerged as a promising therapeutic tool against hepatocellular carcinoma (HCC). Liver transplantation (LT) remains the primary option for curing HCC; however, post-transplant tumor recurrence and the development of new malignancies significantly impact patient prognosis. The application of immune cell therapy in LT for HCC may reestablish antitumor immunity following transplantation without increasing the risk of rejection. In this review, we provide a concise overview of the suppressive tumor-immune status and its impact on tumor recurrence and the development of neoplastic tumors after LT for HCC. We also examine the latest cellular cancer immunotherapy regimens for solid tumors, with a particular focus on HCC, and discuss their limitations. Finally, we summarize the challenges of applying cellular cancer immunotherapy in LT, including the potential induction of acute rejection and the suppressive effects of immunosuppressive agents, as well as potential coping strategies. In conclusion, cellular cancer immunotherapy may offer a potentially effective treatment for tumor recurrence in LT for HCC.</p>\n </div>","PeriodicalId":10467,"journal":{"name":"Clinical Transplantation","volume":"39 9","pages":""},"PeriodicalIF":1.9000,"publicationDate":"2025-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Transplantation","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/ctr.70313","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"SURGERY","Score":null,"Total":0}

引用次数: 0

Abstract

Immunocytotherapy has emerged as a promising therapeutic tool against hepatocellular carcinoma (HCC). Liver transplantation (LT) remains the primary option for curing HCC; however, post-transplant tumor recurrence and the development of new malignancies significantly impact patient prognosis. The application of immune cell therapy in LT for HCC may reestablish antitumor immunity following transplantation without increasing the risk of rejection. In this review, we provide a concise overview of the suppressive tumor-immune status and its impact on tumor recurrence and the development of neoplastic tumors after LT for HCC. We also examine the latest cellular cancer immunotherapy regimens for solid tumors, with a particular focus on HCC, and discuss their limitations. Finally, we summarize the challenges of applying cellular cancer immunotherapy in LT, including the potential induction of acute rejection and the suppressive effects of immunosuppressive agents, as well as potential coping strategies. In conclusion, cellular cancer immunotherapy may offer a potentially effective treatment for tumor recurrence in LT for HCC.

查看原文本刊更多论文

细胞癌免疫治疗在肝移植人群HCC：一个有吸引力的治疗选择在未来十年

免疫细胞疗法已成为治疗肝细胞癌（HCC）的一种有前途的治疗工具。肝移植（LT）仍然是治疗HCC的主要选择；然而，移植后肿瘤复发和新的恶性肿瘤的发展显著影响患者的预后。在肝细胞癌肝移植中应用免疫细胞疗法可以在不增加排斥风险的情况下重建移植后的抗肿瘤免疫。在这篇综述中，我们简要概述了肝癌肝移植后抑制肿瘤免疫状态及其对肿瘤复发和肿瘤发展的影响。我们还研究了针对实体瘤的最新细胞癌免疫治疗方案，特别关注HCC，并讨论了它们的局限性。最后，我们总结了在LT中应用细胞癌免疫治疗的挑战，包括急性排斥反应的潜在诱导和免疫抑制剂的抑制作用，以及潜在的应对策略。总之，细胞癌免疫治疗可能是肝细胞癌肝移植复发的潜在有效治疗方法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical Transplantation 医学-外科

CiteScore

3.70

自引率

4.80%

发文量

286

审稿时长

2 months

期刊介绍： Clinical Transplantation: The Journal of Clinical and Translational Research aims to serve as a channel of rapid communication for all those involved in the care of patients who require, or have had, organ or tissue transplants, including: kidney, intestine, liver, pancreas, islets, heart, heart valves, lung, bone marrow, cornea, skin, bone, and cartilage, viable or stored. Published monthly, Clinical Transplantation’s scope is focused on the complete spectrum of present transplant therapies, as well as also those that are experimental or may become possible in future. Topics include: Immunology and immunosuppression; Patient preparation; Social, ethical, and psychological issues; Complications, short- and long-term results; Artificial organs; Donation and preservation of organ and tissue; Translational studies; Advances in tissue typing; Updates on transplant pathology;. Clinical and translational studies are particularly welcome, as well as focused reviews. Full-length papers and short communications are invited. Clinical reviews are encouraged, as well as seminal papers in basic science which might lead to immediate clinical application. Prominence is regularly given to the results of cooperative surveys conducted by the organ and tissue transplant registries. Clinical Transplantation: The Journal of Clinical and Translational Research is essential reading for clinicians and researchers in the diverse field of transplantation: surgeons; clinical immunologists; cryobiologists; hematologists; gastroenterologists; hepatologists; pulmonologists; nephrologists; cardiologists; and endocrinologists. It will also be of interest to sociologists, psychologists, research workers, and to all health professionals whose combined efforts will improve the prognosis of transplant recipients.